Job Abstract

Since PAXLOVID’s emergency use authorization on 12/22/21, PAXLOVID has helped treat over 19 M patients at high-risk from progression to severe COVID-19, which can lead to hospitalization and/or death. Now that PAXLOVID is FDA approved and commercialized in the U.S., this novel protease inhibitor is positioned to remain the gold standard in COVID-19 treatment, despite competitive entry expected in 2025. Significant opportunity to increase treatment rates for eligible patients and bolster PAXLOVID... more details

Job Abstracts is an independent Job Search Engine. Job Abstracts is not an agent or representative and is not endorsed, sponsored or affiliated with any employer. Job Abstracts uses proprietary technology to keep the availability and accuracy of its job listings and their details. All trademarks, service marks, logos, domain names, and job descriptions are the property of their respective holder. Job Abstracts does not have its members apply for a job on the jobabstracts.com website. Additionally, Job Abstracts may provide a list of third-party job listings that may not be affiliated with any employer. Please make sure you understand and agree to the website's Terms & Conditions and Privacy Policies you are applying on as they may differ from ours and are not in our control.